CD33 and acute myeloid leukemia: Tambaro and colleagues have described their experience with the Phase I clinical trial evaluating the safety and efficacy of a CD33 targeted CAR with 4-1BB and CD3ζ endo-domains that have been co-expressed with truncated human epidermal growth factor receptor (HER1t) in patients with relapsed and refractory AML (48).